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Colchicine Depolymerizes Microtubules, Increases Junctophilin-2, and
Improves Right Ventricular Function in Experimental Pulmonary
Arterial Hypertension
Kurt W. Prins, MD, PhD;* Lian Tian, PhD;* Danchen Wu, MD, PhD; Thenappan Thenappan, MD; Joseph M. Metzger, PhD;
Stephen L. Archer, MD, FRCP(C), FAHA, FACC
Background-—Pulmonary arterial hypertension (PAH) is a lethal disease characterized by obstructive pulmonary vascular
remodeling and right ventricular (RV) dysfunction. Although RV function predicts outcomes in PAH, mechanisms of RV dysfunction
are poorly understood, and RV-targeted therapies are lacking. We hypothesized that in PAH, abnormal microtubular structure in RV
cardiomyocytes impairs RV function by reducing junctophilin-2 (JPH2) expression, resulting in t-tubule derangements. Conversely,
we assessed whether colchicine, a microtubule-depolymerizing agent, could increase JPH2 expression and enhance RV function in
monocrotaline-induced PAH.
Methods and Results-—Immunoblots, confocal microscopy, echocardiography, cardiac catheterization, and treadmill testing were
used to examine colchicine’s (0.5 mg/kg 3 times/week) effects on pulmonary hemodynamics, RV function, and functional
capacity. Rats were treated with saline (n=28) or colchicine (n=24) for 3 weeks, beginning 1 week after monocrotaline (60 mg/kg,
subcutaneous). In the monocrotaline RV, but not the left ventricle, microtubule density is increased, and JPH2 expression is
reduced, with loss of t-tubule localization and t-tubule disarray. Colchicine reduces microtubule density, increases JPH2 expression,
and improves t-tubule morphology in RV cardiomyocytes. Colchicine therapy diminishes RV hypertrophy, improves RV function, and
enhances RV–pulmonary artery coupling. Colchicine reduces small pulmonary arteriolar thickness and improves pulmonary
hemodynamics. Finally, colchicine increases exercise capacity.
Conclusions-—Monocrotaline-induced PAH causes RV-speciﬁc derangement of microtubules marked by reduction in JPH2 and
t-tubule disarray. Colchicine reduces microtubule density, increases JPH2 expression, and improves both t-tubule architecture and
RV function. Colchicine also reduces adverse pulmonary vascular remodeling. These results provide biological plausibility for a
clinical trial to repurpose colchicine as a RV-directed therapy for PAH. ( J Am Heart Assoc. 2017;6:e006195. DOI: 10.1161/
JAHA.117.006195.)
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P ulmonary arterial hypertension (PAH) is a lethal cardio-vascular disorder with a 1-year mortality rate of 15% to
20% and a median survival of 5 to 7 years after diagnosis.1-3
In PAH, obstructive remodeling of the pulmonary vasculature
and reduced PA compliance increase pulmonary arterial
pressures and right ventricular (RV) workload.4,5 As PAH
progresses, RV function declines, and many patients succumb
from RV failure.6,7 Although RV dysfunction is repeatedly
identiﬁed as the major risk factor for mortality in PAH,8-10 the
4 classes of approved pulmonary hypertension medications
primarily target the pulmonary vasculature, with little evi-
dence of direct beneﬁt to the RV. Although there are data that
phosphodiesterase-5 inhibitors improve RV function in animal
models of PAH,11 an effect on the RV in humans has not been
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proven. Thus, an ideal therapeutic agent for PAH would not
only reduce pulmonary vascular resistance but also augment
RV function.
There is pathological remodeling of the microtubule
cytoskeleton in the RV in pulmonary artery–banded felines12
and rats with monocrotaline (MCT)-induced PAH.13 This
suggested the possibility that targeting microtubules with
colchicine, a microtubule-depolymerizing agent,14 might
improve RV function. Microtubule remodeling causes impro-
per trafﬁcking and subsequent misregulation of junctophilin-2
(JPH2) in mouse models of left ventricular (LV) dysfunc-
tion15,16; however, the role of microtubules in RV dysfunction
is unknown. JPH2 is a protein that is essential for life17
because of its critical roles in maintaining cardiomyocyte
t-tubule structure and regulating calcium handling by gating
the ryanodine receptor.18 Moreover, transgenic19 and virally
mediated overexpression20 of JPH2 augments LV function in
mice with LV dysfunction caused by aortic banding. Although
there is strong evidence that JPH2 plays a signiﬁcant role in
LV dysfunction, little is known about the role of microtubule
structure and JPH2 expression in RV dysfunction associated
with PAH. Colchicine treatment reduces microtubule density
and normalizes JPH2 subcellular localization, which improves
t-tubule architecture in LV cardiomyocytes in mouse models
of LV dysfunction.15,16 However, the effects of colchicine on
the RV are unknown.
Here, we investigated the hypothesis that in PAH abnormal
microtubulular structure in RV cardiomyocytes impairs RV
function by reducing JPH2 expression and adversely altering
t-tubule structure. Conversely, we assessed whether colchicine
could improve RV function in PAH by reducing the microtubule
density and increasing JPH2 expression in RV cardiomyocytes.
We created PAH using the well-validated MCT rat model, which
we selected because it results in RV failure. We injected rats
with either phosphate-buffered saline (PBS) or colchicine
1 week after MCT injection, the time point when pulmonary
vascular disease is ﬁrst detectable.21,22 After 3 weeks of
treatment, we examined the effects of colchicine therapy on
microtubule density, JPH2 protein levels and localization
patterns, t-tubule morphology, RV size and function, pulmonary
vascular disease severity, RV–pulmonary artery (PA) coupling,
exercise capacity, and survival. In MCT-PAH we show a
RV-restricted reduction in JPH2 expression leading to cham-
ber-speciﬁc t-tubule derangements. Colchicine therapy in vivo
increases JPH2 expression and attenuates t-tubule remodeling.
The beneﬁcial effects of RV cardiomyocyte ultrastructure are
associated with improvements in RV function. RV-PA coupling is
enhanced in rats treated with colchicine, indicating a direct
beneﬁcial effect on the RV. However, an additional advantage of
colchicine is that it reduces the severity of pulmonary vascular
disease. Finally, colchicine treatment improves exercise capac-
ity. The observed beneﬁts of colchicine on JPH2 expression,
t-tubule structure, RV-PA coupling, and functional capacity
suggest that a trial to repurpose colchicine to treat PAHmay be
reasonable.
Materials and Methods
Animal Models
Male Sprague-Dawley rats were purchased from Charles
Rivers Laboratories (Charles River, QC, Canada). Rats received
subcutaneous injections of MCT (60 mg/kg; Sigma-Aldrich,
St. Louis, MO) (n=52) or PBS (n=16). Experiments were
conducted in accordance with published guidelines of the
Canadian Council of Animal Care and approved by Queen’s
University Animal Care Committee.
Chronic Colchicine Treatment
One week after induction of PAH with MCT, a time point
that corresponds to the onset of detectable pulmonary
vascular disease but early in the course of evolution of
PAH,21,22 rats were treated with intraperitoneal injections of
0.5 mg/kg ﬁlter-sterilized colchicine (Sigma-Aldrich, St.
Louis, MO) dissolved in PBS (n=24) or an equivalent volume
of PBS (n=28) on Monday, Wednesday, and Friday for
3 weeks and were then analyzed. A sample size of 25 to 30
was targeted for 3 reasons: there were 3 groups in the
analysis, to reduce effects of the heterogeneity with
colchicine treatment, and to account for possible deaths
during the experimental time frame. The dosing scheme was
implemented as similar doses were shown to depolymerize
the microtubule cytoskeleton in cardiomyocytes in rats23,24
but less than doses that are associated with signiﬁcant
cardiotoxicity in rats.25 Four weeks after MCT injection was
the end point of the study because a previous study had
shown that time frame was associated with severe
pulmonary hypertension.21
Clinical Perspective
What Is New?
• Microtubule remodeling leads to RV–speciﬁc misregulation
of junctophilin-2, resulting in t-tubule disruptions and RV
dysfunction in monocrotaline rats.
• Colchicine-induced microtubule depolymerization increases
junctophilin-2, improves t-tubule morphology, and enhances
RV function and exercise capacity in monocrotaline rats.
What Are the Clinical Implications?
• These data suggest that colchicine could be repurposed as a
RV–directed therapy for PAH.
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Antibodies
Polyclonal antibodies for voltage-gated calcium channel
(Sigma-Aldrich, St. Louis, MO) and JPH2 (ThermoScientiﬁc,
Waltham, MA) and monoclonal antibodies for a-tubulin
(Sigma-Aldrich) and b-tubulin (Sigma-Aldrich) were used.
Secondary antibodies, Alexa Fluor-488 or Alexa Fluor-568
conjugated antirabbit or antimouse antibodies, were
purchased from Molecular Probes (Eugene, OR). Infrared
dye–conjugated antimouse and antirabbit antibodies were
purchased from LICOR Biosciences (Lincoln, NE).
Cardiomyocyte Isolation
Isolation of control RV cardiomyocytes was performed as
described previously.26 Brieﬂy, adult rat hearts were enzymat-
ically digested via retrograde perfusion with collagenase. After
digestion, the RV was isolated and then cut into small pieces
and triturated to single cardiomyocytes. Cardiomyocytes were
plated on laminin-coated coverslips, and after 1 hour, cells
were bathed with M-199 media (Sigma-Aldrich, St. Louis, MO,
USA) supplemented with 10 mmol/L HEPES, 26.2 mmol/L
sodium bicarbonate, 0.02% bovine serum albumin, and 50 U/
mL penicillin-streptomycin, insulin (5 lg/mL), transferrin
(5 lg/mL), and selenite (5 ng/mL).
Paclitaxel Treatment in Isolated Cardiomyocytes
Isolated control cardiomyocytes were cultured as described
above. To evaluate the effects of microtubule stabilization,
which is a pathologic feature of RV dysfunction, we admin-
istered the microtubule-stabilizing agent paclitaxel (Cytoskele-
ton, Denver, CO)27 (20 lmol/L) dissolved in dimethyl
sulfoxide (DMSO) (Sigma-Aldrich) or an equivalent volume of
DMSO for a total of 24 hours.
Western Blot Analysis and Quantiﬁcation
Immunoblots were performed on RV and LV specimens, as
described.16 Protein concentration was determined using a
bicinchoninic acid protein assay kit (Pierce, Waltham, MA).
Sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) was performed with 25 lg of protein extracts
and then transferred to nitrocellulose membrane. Membranes
were washed/blocked in 5% milk in PBS for 1 hour and
incubated with primary antibodies for 1 hour at room
temperature. Subsequently, membranes were again washed
and blocked twice for 10 minutes in 5% milk in PBS and then
incubated with infrared secondary antibodies for 30 minutes
at room temperature. Finally, membranes were washed twice
for 5 minutes in Tris-buffered saline containing 0.1% Tween
(Sigma-Aldrich). Quantiﬁcation of Western blots was per-
formed on an Odyssey Infrared Imaging system (Lincoln, NE).
Posttransfer SDS-PAGE gels were stained with Coomassie
brilliant blue and imaged at the 700-nm wavelength on the
Odyssey Imaging system as the loading control, with the band
corresponding to the myosin heavy chain used as the
reference.16
T-Tubule Analysis
Primary cardiomyocytes and 10-lm RV and LV cryosections
were ﬁxed with 4% paraformaldehyde for 10 minutes at
37°C, washed twice for 5 minutes with PBS, incubated with
Alexa Fluor-488 conjugated wheat germ agglutinin (Sigma-
Aldrich) for 10 minutes at room temperature, and then
washed in PBS twice for 5 minutes and mounted in Anti-
Fade Reagent (Molecular Probes). Images were collected
using a Bio-Rad (Hercules, CA) MRC 1000 scan head
mounted on an upright Nikon Optishot (Tokyo, Japan)
microscope at the University of Minnesota Imaging Center.
Z-stacks were collected and converted into a Z-projection
using ImageJ (National Institutes of Health, Bethesda, MD).
T-tubule structure and regularity were quantiﬁed using the
TTPower plugin on ImageJ, which uses fast Fourier trans-
formation to quantitate the regularity of t-tubules as
previously described.16,28
Immunoﬂuorescence Analysis
Primary cardiomyocytes and 10-lm RV or LV cryosections
were ﬁxed in 4% paraformaldehyde for 10 minutes at 37°C,
permeabilized with 1% Triton X-100 (Sigma-Aldrich) in PBS,
blocked in 5% bovine serum albumin (BSA) in PBS for
10 minutes 3 times, and incubated with primary antibodies
overnight at 4°C. Slides were then washed and blocked
with 5% BSA in PBS for 10 minutes 3 times and then
incubated with Alexa Fluor-488 or Alexa Fluor-568 conju-
gated secondary antibodies for 30 minutes at 37°C. Then,
slides were washed with PBS and mounted in Anti-Fade
Reagent (Molecular Probes). Confocal micrographs were
collected as described above. JPH2 localization was
quantiﬁed using the TTPower plugin on ImageJ as
described.16
Image Processing
Confocal images were collected and processed using identical
settings to optimize image quality in Adobe Photoshop
Version CS6 (San Jose, CA).
Echocardiography
Echocardiography was performed using a Vevo2100 ultra-
sound system with a 37.5-MHz transducer (Visual Sonics Inc,
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Toronto, ON, Canada). Rats were lightly anesthetized with
isoﬂurane (1.6% to 2.0%), and chest hair was removed using a
depilatory cream (Nair; Carter-Horner, Mississauga, ON,
Canada). M-mode and 2-D modalities were applied to measure
RV free wall (RVFW) thickness during end diastole and end
systole and tricuspid annular plane systolic excursion
(TAPSE). PA diameter was measured at the level of pulmonary
outﬂow tract during midsystole. Pulsed-wave Doppler was
used to measure PA acceleration time and PA ﬂow velocity
time integral. RV ejection time was measured as the interval
from the onset to the end of ejection in milliseconds, as
previously described.21 Stroke volume, cardiac output, and
cardiac index were calculated as previously described.21
Representative images are depicted in Figure S1.
Right Ventricular-Pulmonary Artery Coupling
RV-PA coupling was deﬁned 2 ways: TAPSE divided by
invasively measured mean pulmonary artery pressure (mPAP)
and percentage change in RVFW thickness/mPAP as previ-
ously described.29-33
Treadmill Walk Distance
Exercise capacity was tested by measuring maximal distance
run on a motorized treadmill (Simplex II Instrument; Columbus
Instruments, Columbus, OH). The initial treadmill speed was
10 m/min and increased 5 m/min every 5 minutes for
30 minutes or until the rat fatigued.
Right Heart Catheterization
Rats were anesthetized with intraperitoneal injection of a
cocktail containing ketamine (75 mg/kg) and xylazine
(10 mg/kg). During catheterization, rats were intubated and
ventilated. A ﬂuid-ﬁlled polyethylene catheter was used to
measure RV pressure, systolic pulmonary artery pressure and
mPAP in anesthetized, closed-chest rats. High-ﬁdelity pres-
sures were recorded and analyzed using a PowerLab 8/35
data acquisition module and LabChart 8.1 software (ADInstru-
ments, Colorado Spring, CO). Cardiac output was measured
by the thermodilution method.21 Total pulmonary resistance
was calculated as mPAP/cardiac output.
Survival Analysis
Rats were deﬁned as dead for purposes of survival calculation
if they were found dead by investigators or were too ill for
continued study and thus required euthanasia per criteria
established by the Queen’s University Veterinary staff
(including more than 10% loss in body weight and failure to
feed).
Lung Histology
Lungs were perfused with 10% formalin at a pressure of
25 cm H2O for 1 hour. After ﬁxation in formalin, lungs were
frozen in melting isopentane, cryosectioned, and stained with
hematoxylin and eosin. Percentage medial thickness of small
pulmonary arterioles (20 to 200 lm in diameter) was
calculated as 100 times (outer diameterinner diameter)/
outer diameter,34 using ImageJ software (NIH).
Cardiomyocyte Fiber Diameter Analysis
RV cardiomyocyte diameter was quantiﬁed from transverse
sections of the RVFW. The extracellular matrix was labeled
with Alexa Fluor-488 conjugated wheat germ agglutinin, and
confocal micrographs were collected as described above. The
greatest diameter of the cardiomyocytes was calculated using
ImageJ software (NIH).
Statistics
All data are represented as meanstandard error of the
mean. Unpaired t test was used for comparing means of 2
groups, and analysis of variance with Tukey post hoc test was
used to compare means among 3 groups. The relationship
between mPAP and RV function was analyzed using linear
correlational analysis. A Kaplan-Meier survival curve was
constructed to determine survival differences using a log-rank
test to statistically assess differences in survival. All statistical
analysis was performed using GraphPad Prism (V7.01; LaJolla,
CA). Statistical signiﬁcance was deﬁned by P<0.05.
Results
Consistent with a previous report,13 the microtubule
cytoskeleton was pathologically remodeled in the RV of
MCT rats. Relative to controls, RV expression of a- and
b-tubulin, individual microtubule subunits, was elevated over
2.5-fold in MCT RV extracts (Figure S2A and S2B). Moreover,
immunoﬂuorescence analysis of RV cryosections revealed an
increase in the microtubule density in the RVs of MCT rats
(Figure S2C).
Next, we assessed the effects of colchicine on JPH2 and t-
tubule morphology in the RV of MCT-PAH rats. Colchicine
reduced microtubule density in the RV (Figure 1A) and
signiﬁcantly increased JPH2 expression in MCT RV extracts,
measured in arbitrary units (AU) (PBS 10011 AU, MCT
448 AU, and MCT-colchicine 819 AU) (Figure 1B and 1C).
Levels of another important t-tubule protein, voltage-gated
calcium channels, were unaltered in RV extracts from MCT-
PAH and did not change with colchicine therapy (Figure 1B
and 1C). Analysis of the subcellular localization of JPH2
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revealed loss of the regular striated staining pattern inMCTRVs,
which colchicine signiﬁcantly improved (PBS 70.61.6 AU,
MCT 25.23.0 AU, MCT-colchicine 36.62.7 AU) (Figure 1D
and 1E). Finally, t-tubule staining showed near complete
loss of t-tubule architecture in the RVs of MCT rats, which
colchicine signiﬁcantly mitigated (PBS 65.72.9 AU, MCT
30.62.7 AU, MCT-colchicine 50.13.5 AU) (Figure 1F
and 1G).
To further test the relationship between microtubular
remodeling and JPH2 and t-tubule morphology in RV car-
diomyocytes, we examined the effects of paclitaxel on JPH2
localization patterns and t-tubule morphology in control
isolated RV cardiomyocytes. After exposure to paclitaxel for
24 hours, the regular striated pattern of JPH2 was decreased
(DMSO 75.41.9 AU, paclitaxel 68.11.9 AU, P=0.01). This
was accompanied by t-tubule remodeling characterized by the
emergence of discontinuous t-tubules (DMSO 55.21.6 AU,
paclitaxel 44.93.2 AU, P=0.006) (Figure 2A through 2D).
Thus, the adverse effects of microtubule stabilization on JPH2
and t-tubules were observed whether microtubules were
chemically disordered by paclitaxel in normal myocytes or as
part of the disease process in cardiomyocytes from MCT RVs.
Next, we analyzed the chamber speciﬁcity of microtubule
and JPH2 misregulation and subsequent t-tubule morphology.
In LV extracts, a-tubulin was nonsigniﬁcantly reduced in the
MCT LV but was signiﬁcantly reduced in the MCT-colchicine LV
(PBS 1.00.08, MCT 0.880.06 AU, and MCT-colchicine
0.590.07 AU) (Figure S3A and S3B). In contrast to the RV,
JPH2 protein levels were signiﬁcantly elevated in MCT LV and
were even higher in MCT-colchicine LV (PBS 1.00.07, MCT
Figure 1. Colchicine increases JPH2 protein levels, restores JPH2
to t-tubules, and mitigates pathological t-tubule remodeling in the
RV in MCT rats. A, Confocal micrographs of RV sections stained
with a b-tubulin antibody (green) to delineate microtubules.
Microtubules are depolymerized in the MCT-colchicine rats, and
MCT rats have increased microtubule density as compared with
PBS controls. B, Representative Western blots from 3 PBS, MCT,
and MCT-colchicine RV extracts and (C) quantiﬁcation of VGCC
(PBS 1017 AU, n=5; MCT 10416 AU, n=5; and MCT-colchicine
956 AU, n=5) and JPH2 (PBS 10011 AU, n=5, MCT 448 AU,
n=10; and MCT-colchicine 819 AU, n=10). Colchicine treatment
signiﬁcantly increases JPH2 expression. D, Confocal micrographs of
RV sections stained for JPH2 (green). The striated pattern of JPH2 is
partially restored with colchicine treatment. (PBS 70.61.6 AU,
n=54 cells from 3 animals, MCT 25.23.0 AU, n=50 cells from 3
animals, MCT-colchicine 36.62.7 AU, n=46 cells from 3 animals)
(E). Confocal micrographs of RV sections stained with WGA (green)
to label t-tubules (F). Colchicine treatment improves t-tubule
architecture (PBS 65.72.9 AU, n=49 cells from 3 animals, MCT
30.62.7 AU, n=50 cells from 3 animals, MCT-colchicine
50.13.5 AU, n=45 cells from 3 animals) (G). *Signiﬁcantly
different from PBS; #signiﬁcantly different from MCT rats as
determined by 1-way ANOVA with Tukey post hoc analysis. Scale
bar: 5 lm in all images. AU indicates arbitrary units; CBB,
Coomassie brilliant blue; Colch, colchicine; JPH2, junctophilin-2;
MCT, monocrotaline; PBS, phosphate-buffered saline; RV, right
ventricle; VGCC, voltage-gated calcium channel; WGA, wheat germ
agglutinin.
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1.60.14, MCT-colchicine 2.10.08) (Figure S3A and S3B).
There were no signiﬁcant differences in JPH2 localization
patterns (PBS 47.12 AU, MCT 51.72.8 AU, MCT-colchicine
51.53.3 AU) and t-tubule architecture (PBS 58.81.2 AU,
MCT 61.21.7 AU, MCT-colchicine 60.21.3 AU) (Figure S3C
through S3F) among control, MCT, and MCT-colchicine LVs.
Thus, the misregulation of JPH2 and changes in t-tubule
architecture were speciﬁc to the RV in MCT rats.
Then, we examined the impact of colchicine on RV
morphology in MCT rats. Colchicine signiﬁcantly reduced RV
cardiomyocyte diameter (PBS 15.10.2 lm, MCT
23.90.3 lm, MCT-colchicine 21.00.2 lm) (Figure 3A and
3B). Colchicine also signiﬁcantly blunted RV hypertrophy as
quantiﬁed by diastolic RVFW thickness (PBS 0.60.03 mm,
MCT-PBS 1.50.10 mm, MCT-colchicine 1.00.07 mm) (Fig-
ure 3C) and the Fulton index (PBS 0.210.01, MCT-PBS
0.670.02, MCT-colchicine 0.480.03) (Figure 3D).
Colchicine treatment augmented RV function in vivo as
measured by echocardiography and cardiac catheterization.
All indices of RV function were signiﬁcantly improved in MCT-
PAH rats treated with colchicine: TAPSE (PBS 2.90.01 mm,
MCT 1.90.08 mm, MCT-colchicine 2.40.10 mm) (Fig-
ure 4A), percentage change in RVFW thickness (PBS
949%, MCT 243%, MCT-colchicine 546%) (Figure 4B),
and cardiac output (PBS 1337 mL/min, MCT 673 mL/
min, MCT-colchicine 936 mL/min) (Figure 4C). Consistent
with echocardiography data, colchicine signiﬁcantly enhanced
invasively measured hemodynamics: thermodilution cardiac
output (PBS 1308 mL/min, MCT 425 mL/min, MCT-
colchicine 678 mL/min) (Figure 4D) and cardiac index
(PBS 0.270.02 mL/[ming], MCT 0.110.10 mL/[ming],
MCT-colchicine 0.190.02 mL/[ming]) (Figure 4E).
We also examined the relationships between RV JPH2
expression and RV size and function in vivo. There was an
Figure 2. Paclitaxel induces JPH2 mislocalization and t-tubule disruptions in cultured control rat RV
cardiomyocytes. A, Representative confocal micrographs of isolated RV cardiomyocytes stained with JPH2
antibody (green). B, Quantiﬁcation of JPH2 localization patterns (DMSO 75.41.9, paclitaxel 68.11.9,
P=0.01). Paclitaxel treatment partially disrupts the striated JPH2 staining pattern. C, Confocal micrographs
of isolated cardiomyocytes stained with WGA (green) to delineate t-tubules. D, Quantiﬁcation of t-tubule
architecture (DMSO 55.21.6, paclitaxel 44.93.2, P=0.006). Paclitaxel treatment induces t-tubule
remodeling. Scale bar: 5 lm. *P<0.05 as determined by t test. DMSO indicates dimethyl sulfoxide; JPH2,
junctophilin-2; RV, right ventricle; WGA, wheat germ agglutinin.
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inverse association between JPH2 levels and diastolic RVFW
thickness (r=0.58, P=0.002) (Figure 5A). RV function, as
determined by percentage change in RVFW thickness (r=0.67,
P=0.0003) (Figure 5B) and TAPSE (r=0.54, P=0.005) (Fig-
ure 5C), was positively associated with JPH2 expression.
Thus, reduced levels of JPH2 were associated with RV
hypertrophy and RV dysfunction.
In addition to the beneﬁcial effects on the RV, colchicine
mitigated adverse pulmonary vascular remodeling. The per-
centage medial thickness of small intrapulmonary arterioles
Figure 3. Colchicine reduces right ventricular hypertrophy in MCT rats. A, WGA stained RVFW sections. B,
Quantiﬁcation of cardiomyocyte diameter using a box-and-whisker plot. Whiskers extend from 10th to 90th
percentile. (PBS 15.10.2 lm, n=617 cells from 3 animals, MCT 23.90.3 lm, n=474 cells from 3
animals, MCT-colchicine 21.00.2 lm, n=584 cells from 3 animals.) Colchicine signiﬁcantly reduces RV
cardiomyocyte diameter. C, Quantiﬁcation of diastolic RVFW thickness on echocardiography. (PBS
0.60.03 mm, n=16, MCT-PBS 1.50.10 mm, n=21, MCT-colchicine 1.00.07 mm, n=22.) D, Fulton
index in isolated hearts. (PBS 0.210.01, n=12, MCT 0.670.02, n=15, MCT-colchicine 0.480.03, n=16.
Colchicine blunts RV hypertrophy. *Signiﬁcantly different from PBS; #signiﬁcantly different from MCT rats
as determined by 1-way ANOVA with Tukey post hoc analysis. Scale bar: 50 lm. Colch indicates colchicine;
MCT, monocrotaline; PBS, phosphate-buffered saline; RVFW, right ventricle free wall; RV/LV+S, RV free wall
mass/LV and septal mass; WGA, wheat germ agglutinin.
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was signiﬁcantly reduced with colchicine treatment (PBS
13.50.6%, MCT 43.41.5%, MCT-colchicine 39.51.1%)
(Figure 6A and 6B). Consistent with this ﬁnding, colchicine
signiﬁcantly prolonged PA acceleration time (PBS 331 mil-
liseconds, MCT 171 milliseconds, MCT-colchicine 221 mil-
liseconds) (Figure 6C).Likewise,colchicinesigniﬁcantly reduced
mPAP (PBS 121 mm Hg, MCT 413 mm Hg, MCT-colchicine
293 mm Hg) (Figure 6D) and total pulmonary resistance (PBS
0.10.01 mm Hg/[mLmin], MCT 0.90.1 mm Hg/[mLmin],
MCT-colchicine 0.50.1 mm Hg/[mLmin]) (Figure 6E).
To determine whether the observed improvements in RV
function were simply due to regression of pulmonary vascular
disease, we analyzed RV-PA coupling. Consistent with a
direct effect on the RV, colchicine improved RV-PA
coupling as quantiﬁed by TAPSE/mPAP (PBS 0.240.03 mm/
mm Hg, MCT 0.050.01 mm/mm Hg, MCT-colchicine
0.110.02 mm/mm Hg) (Figure 7A) or percentage change in
RVFW thickness/mPAP (PBS 8.91.4%/mm Hg, MCT
0.60.1%/mm Hg, MCT-colchicine 2.70.5%/mm Hg) (Fig-
ure 7B). To further probe RV-PA coupling, the relationship
between RV function (TAPSE and percentage change in RVFW
thickness) and mPAP was examined. There were inverse
relationships among TAPSE (r=0.73, P=0.0003), percentage
change in RVFW thickness (r=0.77, P<0.0001), and mPAP
when PBS and MCT rats were combined (Figure 7C and 7D);
however, in the MCT-colchicine rats the relationships between
RV function and mPAP were lost (TAPSE r=0.17, P=0.56,
percentage change in RVFW thickness r=0.35, P=0.22)
(Figure 7E and 7F).
Finally, we probed whole-animal physiology to assess
tolerability and therapeutic efﬁcacy of colchicine. Colchicine
was well tolerated as there was no difference in end-of-study
mass between MCT and MCT-colchicine rats (PBS 46413 g,
MCT 35010 g, and MCT-colchicine 3448 g) (Figure 8A).
Colchicine signiﬁcantly improved treadmill walk distance
Figure 4. Colchicine therapy improves in vivo RV function in MCT
rats. On echocardiography, TAPSE (PBS 2.90.01 mm, n=16,
MCT 1.90.08 mm, n=21, MCT-colchicine 2.40.10 mm, n=22)
(A), percentage change in RVFW thickness (PBS 949%, n=16, MCT
243%, n=21, MCT-colchicine 546%, n=22) (B), and estimated
cardiac output (CO) (PBS 1337 mL/min, n=16, MCT 673 mL/
min, n=21, MCT-colchicine 936 mL/min, n=22) (C) are all
improved with colchicine treatment in MCT rats. Right heart
catheterization-derived thermodilution CO (PBS 1308 mL/min,
n=5, MCT 425 mL/min, n=10, MCT-colchicine 678 mL/min,
n=13) (D) and cardiac index (PBS 0.270.02 mL/[ming], n=5, MCT
0.110.10 mL/[ming], n=10, MCT-colchicine 0.190.02 mL/
[ming], n=13) (E) are increased with colchicine treatment in MCT
rats. *Signiﬁcantly different from PBS, #signiﬁcantly different from
MCT rats as determined by 1-way ANOVA with Tukey post hoc
analysis. Colch indicates colchicine; MCT, monocrotaline; PBS,
phosphate-buffered saline; RVFW, right ventricle free wall; TAPSE,
tricuspid annular plane systolic excursion.
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when compared with MCT (PBS 19215 m, MCT 92 m,
MCT-colchicine 4411 m) (Figure 8B). Finally, there was a
trend for reduced mortality in the colchicine-treated group
(mortality rates at study completion: PBS 0%, MCT 29%, and
MCT-colchicine 12%, P=0.13) (Figure S4).
Discussion
In this study we show that pathologic and chamber-speciﬁc
remodeling of the microtubule cytoskeleton is associated with
reduced JPH2 expression and t-tubule disarray in RV car-
diomyocytes in MCT-PAH. These molecular and cellular
changes are accompanied by RV dysfunction. We further
demonstrate that colchicine-induced microtubule depolymer-
ization increases JPH2 expression and improves t-tubule
architecture in the RV. Moreover, in vivo colchicine therapy
improves RV function and augments cardiac output while
decreasing RV hypertrophy. Colchicine also has beneﬁcial
effects on the pulmonary vasculature with a decrease in
percentage medial thickness of small pulmonary arterioles, a
reduction in mPAP and total pulmonary resistance, and
prolongation of the PA acceleration time. However, colchi-
cine’s beneﬁcial effects on RV function are not solely due to
reduced afterload, as is evident from its ability to enhance RV-
PA coupling. Finally, colchicine increases exercise capacity.
Collectively, these data suggest that colchicine has the
potential to improve RV function in PAH by increasing JPH2
and improving t-tubule morphology.
Our ﬁndings provide further evidence that pathological
microtubule cytoskeletal remodeling causes JPH2 misregula-
tion and t-tubule disruptions in cardiomyocytes. In vivo
microtubule depolymerization with colchicine restores JPH2
localization to the t-tubules and corrects t-tubule morphology
in an aortic-banding heart failure model.15 Our ﬁndings are
consistent with prior studies showing that nocodazole-
mediated microtubule depolymerization rescues JPH2
mislocalization and t-tubule remodeling in cultured cardiomy-
ocytes.15 Conversely, microtubule stabilization (achieved
using paclitaxel) recapitulates the microtubule phenotype
observed in pressure-overloaded and failing cardiomyocytes
leading to JPH2 mislocalization and t-tubule irregularities.15
Consistent with this, we demonstrate that paclitaxel induces
JPH2 mislocalization and t-tubule disarray in control RV
cardiomyocytes (Figure 2). Thus, there is a clear relationship
between microtubule structure and JPH2 expression in both
RV and LV cardiomyocytes.
Colchicine-induced microtubule depolymerization increa-
ses JPH2 and corrects t-tubule morphology in vivo in a mouse
model of Duchenne muscular dystrophy16 and aortic band-
ing.15 Our study extends these ﬁndings to the RV and
demonstrates that proper regulation of JPH2 and subsequent
t-tubule structure requires a normal microtubule cytoskeleton
in both ventricles. However, although the molecular pathway
may be similar in LV and RV dysfunction, the changes in the
microtubules-JPH2–t-tubule pathway in MCT-PAH are
Figure 5. Reduced JPH2 expression is associated with right
ventricular hypertrophy and RV dysfunction in vivo. JPH2 levels
are inversely associated with diastolic RVFW thickness (r=0.58,
P=0.002) (A) and are positively correlated with RV function as
determined by percentage change in RVFW thickness (r=0.67,
P=0.0003) (B) and TAPSE (r=0.54, P=0.005) (C). AU indicates
arbitrary units; JPH2, junctophilin-2; RVFW, right ventricle free
wall; TAPSE, tricuspid annular plane systolic excursion.
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chamber speciﬁc in that the LV is spared (Figure S3). The
current ﬁndings of chamber-speciﬁc increases in microtubule
density, JPH2 dysregulation, and t-tubule remodeling (Figure 1
and Figure S2) indicate that JPH2 downregulation is relevant
to RV dysfunction in experimental PAH, analogous to its role
in the LV disease in various cardiomyopathies.
The ability of colchicine to improve RV-PA coupling
suggests that colchicine has a direct effect on the RV.
However, colchicine also reduces pulmonary vascular remod-
eling (Figure 6), likely due to colchicine’s antimitotic
effects,14,35 but that does not fully explain the enhanced
RV-PA coupling in MCT-colchicine rats. The ability of
colchicine to dissociate the very strong relationship between
RV afterload and RV function demonstrates that colchicine
improves RV-PA coupling (Figure 7). We propose that
increases in JPH2 and improvements in t-tubule morphology
mediate the augmented RV function, which is further
supported by the signiﬁcant relationships between JPH2 and
RV function (Figure 5). These results agree with several
studies showing that reduced levels of JPH2 are associated
with left ventricular dysfunction in animal models36-40 and
human disease states15,41 and that increased expression of
JPH2, achieved via transgenic overexpression,19 antagonism
of miR-24,42 viral-mediated overexpression,20 or inhibition of
calpain proteases,43 improves cardiac function in animal
models of LV dysfunction. Thus, increased JPH2 likely
mediates the improved RV-PA coupling in MCT-colchicine rats.
Although several studies show t-tubule disruption to be
associated with LV dysfunction, there is less information
about the role of t-tubule disarray in RV dysfunction in PAH.
Pathological t-tubule remodeling in the RV of MCT rats is
associated with reduced RV fractional shortening.44 Further-
more, sildenaﬁl treatment early in the development of PAH
normalizes t-tubule structure and increases RV fractional
shortening; however, if sildenaﬁl treatment is initiated later in
the disease, t-tubule morphology and RV function do not
improve to the same extent.44 Here, we show that improve-
ments in t-tubule structure due to colchicine treatment are
associated with augmented RV function. Thus, there appears
to be a direct relationship between t-tubule architecture and
RV function in PAH.
Finally, our ﬁnding that colchicine improves RV function in
PAH is easily translatable into human patients with PAH or
other World Health Organization etiologies of pulmonary
hypertension. Because colchicine is approved by the Food and
Drug Administration, a clinical trial using colchicine in PAH
could be conducted. Dosing would need to be altered when
planning a human trial using colchicine to treat PAH because
Figure 6. Colchicine reduces severity of pulmonary vascular disease in MCT rats. A, Representative hematoxylin and eosin–stained lung
sections showing pulmonary arterioles. B, Box-and-whisker plots of percentage medial thickness (PBS 13.50.6% n=85 arterioles from 3
different animals, MCT 43.41.5% n=78 arterioles from 3 animals, MCT-colchicine 39.51.1% n=81 arterioles from 3 different animals).
Whiskers extend from 10th to 90th percentiles. Colchicine reduces pulmonary arteriolar medial thickness. C, Colchicine increases PA
acceleration time (PBS 331 milliseconds, n=16, MCT 171 milliseconds, n=21, MCT-colchicine 221 milliseconds n=22). Quantiﬁcation of
(D) mPAP (PBS 121 mm Hg, n=5, MCT 413 mm Hg, n=13, MCT-colchicine 293 mm Hg n=14) and (E) TPR (PBS 0.10.01 mm Hg/
[mLmin], n=5, MCT 0.90.1 mm Hg/[mLmin], n=9, MCT-colchicine 0.50.1 mm Hg/[mLmin], n=11) from right heart catheterization.
Colchicine improves pulmonary hemodynamics. *Signiﬁcantly different from PBS, #signiﬁcantly different from MCT rats as determined by 1-way
ANOVA with Tukey post hoc analysis. Scale bar 25 lm. Colch indicates colchicine; MCT, monocrotaline; mPAP, mean pulmonary arterial
pressure; PBS, phosphate-buffered saline; TPR, total pulmonary resistance.
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the dose used in our study could cause signiﬁcant toxicity in
humans. However, a 6-month course of colchicine (0.5 mg
twice a day) is well tolerated in stable heart failure patients
and causes small but signiﬁcant improvements in LV remod-
eling.45 However, in this study the overall functional capacity
and rates of hospitalization and death did not change with
colchicine treatment.45 Although colchicine does not improve
outcomes in patients with left heart failure, there are reasons
to believe that it may be efﬁcacious in PAH. First, the best
evidence for colchicine’s beneﬁts derive from preclinical heart
Figure 7. RV-PA coupling is enhanced with colchicine treatment. Colchicine improves RV-PA coupling as
quantiﬁed by TAPSE/mPAP (PBS 0.240.03 mm/mm Hg, n=7, MCT 0.050.01 mm/mm Hg, n=13, MCT-
colchicine 0.110.02 mm/mm Hg, n=14) (A) or percentage change in RVFW thickness/mPAP (PBS
8.91.4%/mm Hg, n=7, MCT 0.60.1%/mm Hg, n=13, MCT-colchicine 2.70.5%/mm Hg, n=14) (B).
There are signiﬁcant inverse relationships between (C) TAPSE (r=0.73, P=0.0003) and mPAP and (D)
percentage change in RVFW thickness and mPAP in control and MCT rats (r=0.77, P<0.0001) but not in
MCT-colchicine rats: TAPSE and mPAP (r=0.17 P=0.56) (E) and percentage change in RVFW thickness and
mPAP (r=0.35 P=0.22) (F). *Signiﬁcantly different from PBS, #signiﬁcantly different from MCT rats as
determined by 1-way ANOVA with Tukey post hoc analysis. Colch indicates colchicine; MCT, monocrotaline;
mPAP, mean pulmonary arterial pressure; PA, pulmonary artery; PBS, phosphate-buffered saline; RVFW,
right ventricle free wall; TAPSE, tricuspid annular plane systolic excursion.
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failure models induced by pressure overload.15 This contrasts
with the etiology of left heart failure patients, which is usually
due to intrinsic LV dysfunction rather than LV pressure
overload. In contrast, PAH is by deﬁnition a pressure overload
state.46 A second reason to believe that colchicine might be
beneﬁcial in the RV failure associated with PAH is the ﬁnding
that colchicine reduces adverse pulmonary vascular remod-
eling (Figure 6) in addition to its direct beneﬁcial effect on RV
function through increased JPH2 expression. Thus, colchicine
could target both afterload and direct cardiac disease
mechanisms in PAH, which may not be the case in many
patients with LV failure.
Limitations
Because colchicine was administered in the early stages in
PAH in the MCT model, it is unclear whether colchicine
prevented or regressed RV t-tubule remodeling as a basis for
the observed improvement in RV function.
Conclusion
Colchicine improves RV function and regresses pulmonary
vascular disease in the MCT-PAH model. However, enhanced
RV-PA coupling in rats treated with colchicine provides
evidence of a RV-speciﬁc effect. Therefore, colchicine has
promise as an RV-targeted therapy for PAH, and thus, a
clinical trial repurposing this therapy could be considered.
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Figure S1. Representative images from echocardiograms from PBS, MCT, and MCT-Colch 
rats.  
 
 (A) Pulse-wave Doppler interrogation of the RVOT.  Distance between dotted red lines signifies 
PA-AT.  (B)  Pulse-wave Doppler of RVOT.  Teal line is used to quantify the VTI for cardiac 
output calculation.  (C) M-mode images used to calculate TAPSE.  Red line shows TAPSE 
values.  (D)  M-modes images of RVFW.  Red line indicates diastolic RVFW thickness.   
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Figure S2. RV microtubule misregulation in MCT rats. 
 
 
(A and B) Representative Western blots and quantification of -(3.0±0.6-fold increase, p=0.018) 
and -tubulin (2.5±0.3-fold increase, p=0.004) protein levels from RV extracts.  CBB: 
Coomassie brilliant blue.  (*) indicates p<0.05 as determined by t-test.  (C) Confocal 
micrographs of RV sections from PBS and MCT rats stained with a -tubulin antibody (green) 
showing increased microtubule density in MCT RV section as compared to PBS control.  Scale 
bar: 10m 
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Figure S3. The LV is spared from JPH2-mediated t-tubule disruptions in MCT rats. 
 
 
 
(A)  Representative Western blots and (B) quantification of -tubulin and JPH2 in LV extracts.  
-tubulin is significantly reduced in MCT-Colch LV extracts.  -tubulin quantification 
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(PBS:1.0±0.08 AU, n=5, MCT:0.88±0.06 AU, n=5, and MCT-Colch:0.59±0.07 AU, n=5).   
JPH2 is increased in both MCT and MCT-Colch LV extracts.  JPH2 quantification 
(PBS:1.0±0.07 AU, n=5, MCT:1.6±0.14 AU, n=5, and MCT-Colch:2.1±0.08 AU, n=5).  (C) 
Confocal micrographs of LV sections labeled with JPH2 antibody (green).  There is normal 
JPH2 localization in all three groups. (PBS:47.1±2.3 AU, n=46 cells from three animals, 
MCT:51.7±2.8 AU, n=40 cells from three animals, MCT-Colch:51.5±3.3 AU, n=40 cells from 
three animals) (D). Confocal micrographs of LV sections stained with WGA (green) to label t-
tubules (E).  Normal t-tubule architecture in all three groups (PBS:58.8±1.2 AU, n=57 cells from 
three animals, MCT:61.2±1.7 AU, n=40 cells from three animals, MCT-Colch:60.2±1.3 AU, 
n=40 cells from three animals) (F).  (*) indicates significantly different from PBS and (#) 
indicates significantly different as compared to MCT rats as determined by one-way ANOVA 
with Tukey post-hoc analysis.  Scale bar: 5 m. 
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Figure S4. Colchicine treatment leads to a nonsignificant reduction in mortality.  Mortality-rates 
at study completion: PBS:0%, MCT:29%, and MCT-Colch:12%, p=0.13. 
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